Thursday, 22 October 2020


Cipla wins $188.95 Mn of Global Fund ARV Tender

14 February 2015 | News | By BioSpectrum Bureau

Cipla wins $188.95 Mn of Global Fund ARV Tender

The contract is effective from the 1st of January 2015 and will run for a period of three years

The contract is effective from the 1st of January 2015 and will run for a period of three years

Singapore: The company has been selected as a 'Panel Supplier' for a Supplier Partnership Agreement.

The contract is effective from the 1st of January 2015 and will run for a period of three years. The supplies will begin from Q4 FY 2015.

Mr Subhanu Saxena, MD and global CEO, Cipla, said: "We are extremely proud to have won this tender from Global Fund. Cipla has been committed to the cause of HIV/AIDS for over two decades and this tender offers us a great opportunity to make HIV/AIDS treatment accessible to more than 140 countries through Global Fund."

Cipla has a long-term association with Global Fund, which started in 2002. Last year, the company has been one of the suppliers who has been awarded with a long-term contract for supplying anti-malarial drugs.

The anti-retrovirals drugs will be manufactured in Cipla's state-of-the-art manufacturing facilities in India, which has been approved by various international regulatory agencies.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account